Oncotelic Therapeutics

OTLC · OTC

$0.0176−$0.0009 (−4.86%)TodayMarket closed · Oct 20, 3:55 PM ET

Prev close $0.0185

About OTLC

Oncotelic Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of anti-vascular therapeutics for patients with cancer and sight-threatening eye diseases. The company is headquartered in Agoura Hills, California and currently employs 38 full-time employees. The firm has three primary drugs and AI technology programs: AL-101 - Intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinson’s Disease (PD), erectile dysfunction (ED) and female sexual dysfunction (FSD); CA4P- a vascular disrupting agent (VDA) - in combination with Ipilimumab for the treatment of solid tumors with focus on melanoma in adult and pediatric melanoma; Oxi4503- a second generation VDA - for the treatment of liquid tumors with focus on childhood leukemia; OT-101 - an antisense against TGF-b2-for the treatment of various cancers and for the treatment of various viruses, and Artemisinin-a natural derivative from an Asian herb Artemisia Annua.

Employees: 38
Headquarters: Agoura Hills, California
Listed: Aug 26, 1993
Sector: Health Care
Industry: Biotechnology
Website: oncotelic.com

Leadership

Oncotelic Therapeutics executives
Name	Title	Since	Age
Vuong Trieu	—	2019	60
Amit Shah	—	—	58
Anthony Maida	—	2020	72
Seymour Fein	—	—	76
Saran Saund	—	—	67
Steven King	—	—	60

Suppliers and customers

Price correlation is over one year: 1 means the stocks move together, -1 opposite

Oncotelic Therapeutics suppliers and customers
Company	Relationship	Country	Correlation
Bristol-Myers Squibb BMY	Supplier and customer	US	0.71
Paloma Partners Management Co.	Supplier and customer	US	—
Arizona State University	Supplier and customer	US	—
Baylor University	Supplier and customer	US	—

Similar companies

Companies in the same industry as Oncotelic Therapeutics

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.